Showing results (31-40 of 121) with videos related to

Sort By:
Pageof 13
World Journal of Urology|April 2, 2025
A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapySiming Li, Jinchang Wei, Huayan Xu, et al.
International Journal of Radiation Oncology, Biology, Physics|March 24, 2024
Efficacy and Safety of Postoperative Adjuvant Radiation Therapy in Resected Nasal Cavity and Paranasal Sinus Mucosal Melanoma: A Combined AnalysisBin Lian, Yue Yang, Baomin Zheng, et al.
Immunotherapy|January 10, 2024
SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanomaXuan Wang, Hongming Pan, Jiuwei Cui, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2019
Identification of a functional polymorphism within the 3'-untranslated region of denticleless E3 ubiquitin protein ligase homolog associated with survival in acral melanomaLu Yang, Jie Dai, Meng Ma, et al.
The British Journal of Ophthalmology|January 18, 2015
Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patientsXinan Sheng, Siming Li, Zhihong Chi, et al.
BMC Medicine|July 2, 2026
Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 studyJuan Li, Huichun Tian, Huayan Xu, et al.
World Journal of Surgical Oncology|November 11, 2025
Efficacy of radiotherapy combined with systemic therapy for retroperitoneal lymph node metastasis in upper tract urothelial carcinoma(UTUC) patients after radical nephroureterectomyXiaoying Li, Xian-Shu Gao, Hongzhen Li, et al.
Frontiers in Immunology|July 22, 2021
Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical TrialsLi Zhou, Xuan Wang, Zhihong Chi, et al.
Cancer Biology & Therapy|May 1, 2018
PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitroXiaowen Wu, Jiayi Yu, Junya Yan, et al.
Melanoma Research|February 22, 2022
Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapyLi Zhou, Yue Yang, Lu Si, et al.
Pageof 13